期刊档案 · ONCOLOGY
Translational Oncology
ISSN 1944-7124 · eISSN 1936-5233 · Neoplasia Press · UNITED STATES
Translational Oncology 中科院 医学 3区（2025 年升级版），影响因子 4.9，完全开放获取，APC 约 3,880 美元，近 24 个月 96 篇文章投稿到接收中位 80 天，录用比例较易（社区反馈），2025 年发文 378 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Translational Oncology 由 Neoplasia Press 出版，属中科院医学大类（2025 升级版3区）。按 OpenAlex 近年发文统计，该刊主要发表 Ferroptosis and cancer prognosis、Cancer Immunotherapy and Biomarkers、Cancer Cells and Metastasis 等主题的论文，这 3 个主题约占 24.4%，主导子领域为 Cancer Research。（根据 OpenAlex 主题统计与中科院分区数据生成）
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials. Translational Oncology does not accept Case Reports.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：ONCOLOGY
主编 Mohammad Asim出版商官网
编委会国家分布：中国大陆 59 位（约 10%）；主要国家 美国 212、中国 59、意大利 51、印度 38、德国 17（共 566 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Ferroptosis and cancer prognosisMedicine9.4%
- Cancer Immunotherapy and BiomarkersMedicine9.1%
- Cancer Cells and MetastasisMedicine5.9%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.5%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.4%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.8%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4.5%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 肿瘤学ONCOLOGY | 3 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 肿瘤学ONCOLOGY | 3 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 肿瘤学ONCOLOGY | 3 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 4.9LetPub ·
- 影响因子（出版商公布）
- 4.9出版商官网 ·
- CiteScore 2026-06
- 7.3LetPub ·
- CiteScore（出版商公布）
- 7.3出版商官网 ·
- SJR 2026-06
- 1.38LetPub ·
- SNIP 2026-06
- 0.91LetPub ·
- h-index
- 39LetPub ·
- h-index
- 97OpenAlex ·
- i10-index
- 1,768OpenAlex ·
- 两年平均被引
- 4.24OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 359LetPub ·
逐年发文量 OpenAlex 统计 · 累计 3,347 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 402 | 402 | 157 |
| 2025 | 378 | 378 | 1,298 |
| 2024 | 396 | 396 | 3,530 |
| 2023 | 241 | 241 | 3,611 |
| 2022 | 272 | 272 | 4,904 |
| 2021 | 321 | 321 | 9,936 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
80 天投稿到接收中位数 · P25–P75 63 天 – 123 天
- 接收到上线
- 中位数 9 天（96 篇）
- 投稿到上线
- 中位数 90 天
- 样本
- 96 篇有投稿与接收日期的文章（窗口内共 963 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 较慢,6-12周LetPub ·
- 平均录用比例（社区反馈）
- 较易LetPub ·
- 投稿到首次决定
- 22 天出版商官网 ·
- 外审后首次决定
- 92 天出版商官网 ·
- 投稿到接收
- 150 天出版商官网 ·
- 接收到发表
- 7 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 22 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 3,880 | 有 | CC BY、CC BY-NC、CC BY-NC-ND | |
| OpenAlex | USD 3,390 / EUR 3,170 / GBP 2,710 / JPY 420,460 | — | — | |
| LetPub | USD 2,930 | 有 | — | |
| 出版商官网 | USD 3,960 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
征稿中的专刊3 个，按截稿日期
- Emerging Insights into the Tumor Immune Microenvironment: Mechanisms, Biomarkers, and Therapeutic Targets截稿
- Advances in Translational Oncology: Integrating Tumor Microenvironment, Biomarkers, and Therapeutic Strategies截稿
- Systemic Inflammation-Metabolism Dysregulation and Cancer: From Fundamental Mechanisms to Precision Therapeutic Interventions截稿
投稿准备要点5 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 1–7 个
- 正文篇幅
- ≤ 4,500 词
- 参考文献格式
- 著者-出版年制
- 投稿信（Cover letter）
- 必须提供
接收的文章类型17 种，含篇幅限制
- commentariesCommentaries are short articles that highlight one or several research papers published in a recent issue of the Journal, placing the results in context for the…未说明篇幅
- commentaryibutions are not considered. Mechanics: Commentaries have a limit of 1,500 words and no more than 10 references. Authors are asked to limit正文 ≤ 1,500 词 · 参考文献 ≤ 10
- editorialsEditorials serve as the voice of Translational Oncology and are written by the Journal's Editors and Guest Editors.未说明篇幅
- lettercted and invited to respond. Mechanics: Letters have a limit of 1,000 words and no more than 10 references. Authors are asked to limit正文 ≤ 1,000 词 · 参考文献 ≤ 10
- letters to the editorTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…未说明篇幅
- letters to the editorsLetters to the Editors which comment directly on work that has previously been published in the Journal will be considered.未说明篇幅
- opinionTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…正文 ≤ 2,500 词 · 参考文献 ≤ 60
- opinion articleOpinions may reflect an individual perception, involvement, or contribution to oncology, and should be prepared in a similar way to a Review.未说明篇幅
- original articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…未说明篇幅
- original research articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…正文 ≤ 4,500 词
- perspectiveTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…正文 ≤ 1,200 词 · 参考文献 ≤ 10
- perspectivesPerspectives are short pieces that aim to highlight for a very broad audience a significant recent development in the field or to raise awareness about a topic …未说明篇幅
- research articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…未说明篇幅
- reviewTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…正文 ≤ 4,500 词
- review articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…正文 ≤ 4,500 词 · 参考文献 ≤ 80
- short communicationTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…未说明篇幅
- spotlightsSpotlights are short articles intended to provide a quick update on one or two recent research articles published in other journals that signify a major advance…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
Single anonymized review process 模型摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
Preprint sharing allowed 模型摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Neoplasia Press
- 出版国家或地区
- UNITED STATES
- 出版语言
- English
- ISSN
- 1944-7124
- 电子版 ISSN
- 1936-5233
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
- 查重政策 ↗DOAJ
常见问题
关于 Translational Oncology 的常见问题
Translational Oncology 是中科院几区期刊？
2025 年升级版分区表中，Translational Oncology 为医学 3区，小类 肿瘤学 3 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Translational Oncology 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 4.9，CiteScore 为 7.3，h-index 为 97。
Translational Oncology 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）96 篇已发表文章登记的日期，投稿到接收的中位数为 80 天（四分位 63–123 天）；投稿社区反馈的平均审稿速度为6–12 周，平均录用比例反馈为“较易”。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Translational Oncology 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：1–7 个；正文篇幅：≤ 4,500 词；参考文献格式：著者-出版年制；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Translational Oncology 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 566 位编委中，中国大陆 59 位（约 10%）；人数最多的国家是 美国（212 位）、中国（59 位）、意大利（51 位）。统计按编委会页面列出的机构国家计，仅供参考。
Translational Oncology 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Translational Oncology 被 SCIE、Scopus、DOAJ 收录。
Translational Oncology 是开放获取期刊吗？版面费多少？
Translational Oncology 为完全开放获取。APC 约 3,880 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。